# Lexeo Therapeutics

Startup profile on Capital Atlas: https://capitalatlas.ai/startups/lexeo-therapeutics

- Industry: Biotechnology
- Headquarters: New York, US
- Website: www.lexeotx.com
- Total disclosed funding: $185M
- Latest round: Series B (Sep 9, 2021)
- Investors on record: 15

## About

Based in New York, US, and founded in 2018 by Ronald G. Crystal, Lexeo Therapeutics, Inc. is a biotechnology company that develops adeno-associated virus (AAV)-mediated therapies. In May 2025, Lexeo Therapeutics, Inc. raised USD 80 million in PIPE funding co-led by Frazier Group and Janus Henderson Investors.  The company trades on NASDAQ under the ticker symbol LXEO. Lexeo Therapeutics develops and provides AAV (adeno-associated virus)-mediated therapies to treat patients with genetic diseases. The company's pipeline includes three clinical-stage gene therapy programs in monogenic diseases and up to 15 potential additional AAV gene therapy programs in monogenic and acquired diseases. The company’s preclinical pipeline includes monogenic diseases as well as hereditary and acquired diseases. The company will use the May 2025 funding to accelerate the development of its cardiovascular drugs.

## Funding rounds

- Series B, Sep 9, 2021, $100M — Alexandria Venture Investments, Invus [DUP], Longitude Capital, Omega Funds, Lundbeckfond Ventures, PBM Capital Group, CAM Capital, Verition Fund Management, Laurion Capital Management, Gray's Creek Capital Partners, Eventide Asset Management, D1 Capital Partners, Janus Henderson Investors, Woodline Partners
- Series A, Jun 1, 2020, $85M — Alexandria Venture Investments, Invus [DUP], Longitude Capital, Omega Funds, Lundbeckfond Ventures, PBM Capital Group, Alzheimer's Drug Discovery Foundation, Janus Henderson Investors, Woodline Partners

## Investors

- Alexandria Venture Investments (https://capitalatlas.ai/funds/alexandria-venture-investments) — Series A, Series B
- Invus [DUP] — Series A, Series B
- Longitude Capital (https://capitalatlas.ai/funds/longitude-capital) — Series A, Series B
- Omega Funds (https://capitalatlas.ai/funds/omega-funds) — Series A, Series B
- Lundbeckfond Ventures (https://capitalatlas.ai/funds/lundbeckfond-ventures) — Series A, Series B
- PBM Capital Group (https://capitalatlas.ai/funds/pbm-capital-group) — Series A, Series B
- Alzheimer's Drug Discovery Foundation — Series A
- Janus Henderson Investors — Series A, Series B
- Woodline Partners — Series A, Series B
- CAM Capital — Series B
- Verition Fund Management — Series B
- Laurion Capital Management — Series B
- Gray's Creek Capital Partners — Series B
- Eventide Asset Management (https://capitalatlas.ai/funds/eventide-asset-management) — Series B
- D1 Capital Partners (https://capitalatlas.ai/funds/d1-capital-partners) — Series B